Recombinant Human PLA2G7/Lp-PLA2 Protein (His Tag)(Active)
| Code | Size | Price |
|---|
| PKSH031390-50ug | 50ug | £656.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Shipping:
This product is provided as lyophilized powder which is shipped with ice packs.
Storage:
Generally lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Further Information
Abbreviation:
PLA2G7;Lp-PLA2
Accession:
Q13093-1
Activity:
Measured by its ability to cleave a colorimetric peptide substrate, 1O-hexadecyl-2-deoxy-2-thio Sacetylsnglyceryl-3-phosphoryl choline (2-Thio-PAF), in the presence of 5, 5?Dithiobis(2-nitrobenzoic acid) (DTNB). The specific activity is > 5000 pmoles/min/ug.
Background:
Platelet-activating factor acetylhydrolase; also known as 1-alkyl-2-acetylglycerophosphocholine esterase; 2-acetyl-1-alkylglycero-phosphocholine esterase; Group-VIIA phospholipase A2; LDL-associated phospholipase A2; PAF 2-acylhydrolase; PLA2G7 and PAFAH; is secreted protein which belongs to theAB hydrolase superfamily and Lipase family. PLA2G7 / PAFAH modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. It has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. PLA2G7 / PAFAH is a potent pro- and anti-inflammatory molecule that has been implicated in multiple inflammatory disease processes; including cardiovascular disease. PLA2G7 also represents an important; potentially functional candidate in the pathophysiology of coronary artery disease (CAD). Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PLA2G7 deficiency). It is a trait which is present in 27% of Japanese. It could have a significant physiologic effect in the presence of inflammatory bodily responses.
Calculated MW:
49.2 kDa
Endotoxin:
< 1.0 EU per ug of the protein as determined by the LAL method.
Expression Host:
HEK293 Cells
Formulation:
Lyophilized from sterile 50mM NaAc, 150mM NaCl, 10% glycerol, pH 5.0
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Fusion tag:
C-His
ObservedMW:
50-55 kDa
Purity:
> 88 % as determined by reducing SDS-PAGE.
Sequence:
Met 1-Asn 441
Target Synonym:
2-acetyl-1-alkylglycerophosphocholine esterase;EC 3.1.1;EC 3.1.1.47;1-alkyl-2-acetylglycerophosphocholine esterase;Group-VIIA phospholipase A2;gVIIA-PLA2;LDL-associated phospholipase A2;LDL-PLA(2);LDL-PLA2;lipoprotein-associated phospholipase A2;LpPLA2;Lp-PLA2;PAF acetylhydrolase;PAF-AH;PAFAHPAF 2-acylhydrolase;phospholipase A2;group VII (platelet-activating factor acetylhydrolase;PLA2G7;plasma);platelet-activating factor acetylhydrolase
UNIProt ID:
Q13093